Big guns see positive sales trend in first quarter
This article was originally published in Clinica
Executive Summary
CR Bard's surgical division had sales of $51 million, up 16%, above the expectations of analysts at Morgan Stanley Dean Witter. The vascular division's sales rose 5% to $61 million, in line with expectations. The company's urology, oncology and "other" divisions were below the analysts' expectations. Urology sales were $92 million, up 3%, oncology sales were up 7% to $65 million, while "other" sales were down 3% to $15 million. The company hopes to save up to $80 million in annual cost savings through various initiatives over the next four years. Baxter's earnings per share rose 9% to $0.71, in line with consensus estimates. For the full year, the company expects low double-digit sales growth with earnings in the mid-teens. In the quarter, Baxter increased its R&D expenditure by 24% to $103 million. Looking beyond 2001, the company envisages sales growth in the low to mid-teens and earnings growth in the mid- to high teens.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.